Abstract
The goal of therapy for patients with advanced-stage Hodgkin lymphoma is to ensure that as many patients as possible are healthy and free of disease decades after completing treatment. To achieve this, the treating physician needs to select the most effective therapeutic regimen, but also needs to choose a treatment strategy that limits long-term toxicity. One approach to achieve this is to use a less intense combination, such as ABVD chemotherapy, as initial treatment and intensify therapy only in those patients who do not become PET negative or who subsequently relapse.
Original language | English (US) |
---|---|
Pages (from-to) | 75-86 |
Number of pages | 12 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2014 |
Keywords
- ABVD chemotherapy
- Escalated BEACOPP
- Event-free survival (EFS)
- Failure-free survival (FFS)
- Hodgkin lymphoma
- Overall survival (OS)
- Response rate
- Toxicity
ASJC Scopus subject areas
- Hematology
- Oncology